Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways

Abstract

In recent years, many therapeutic advances have been made in the management of castration-resistant prostate cancer, with the development and approval of many new drugs. The androgen receptor (AR) is the main driver in prostate cancer growth and progression and the most effective therapeutic agents are still directed against this pathway. Among these, new generation hormonal agents (NHA) including enzalutamide, abiraterone acetate, apalutamide, and darolutamide have shown to improve overall survival and quality of life of prostate cancer patients. Unfortunately, despite the demonstrated benefit, not all patients respond to treatment and almost all are destined to develop a resistant phenotype. Although the resistance mechanisms are not fully understood, the most studied ones include the activation of both dependent and independent AR signalling pathways. Recent findings about multiple growth-promoting and survival pathways in advanced prostate cancer suggest the presence of alternative mechanisms involved in disease progression, and an interplay between these pathways and AR signalling. In this review we discuss the possible mechanisms of primary and acquired resistance to NHA with a focus on AR independent pathways.

Keywords

castration-resistant prostate cancer / androgen receptor signalling / hormonal treatment / enzalutamide / abiraterone / resistance mechanisms

References

[1] Siegel RL,Jemal A.Cancer statistics, 2018..CA Cancer J Clin2018;68:7-30

[2] 2020;AtlantaAmerican Cancer Society23

[3] Sweeney CJ,Carducci M,Jarrard DF.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer..N Engl J Med2015;373:737-46 PMCID:PMC4562797

[4] James ND,Clarke NW,Dearnaley DP.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial..Lancet2016;387:1163-77 PMCID:PMC4800035

[5] Fizazi K,Fein L,Rodriguez-antolin A.Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial..Lancet Oncol2019;20:686-700

[6] Armstrong AJ,Petrylak DP,Villers A.ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer..J Clin Oncol2019;37:2974-86 PMCID:PMC6839905

[7] Chi KN,Bjartell A,Pereira de Santana Gomes AJ.Apalutamide for metastatic, castration-sensitive prostate cancer..N Engl J Med2019;381:13-24

[8] Sumanasuriya S.Treatment of advanced prostate cancer-a review of current therapies and future promise..Cold Spring Harb Perspect Med2018;8:a030635 PMCID:PMC5983161

[9] de Bono JS,Molina A,North S.Abiraterone and increased survival in metastatic prostate cancer..N Engl J Med2011;364:1995-2005 PMCID:PMC3471149

[10] Scher HI,Saad F,Sternberg CN.Increased survival with enzalutamide in prostate cancer after chemotherapy..N Engl J Med2012;367:1187-97

[11] Ryan CJ,Fizazi K,Mulders PFA.Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study..Lancet Oncol2015;16:152-60

[12] Beer TM,Rathkopf DE,Sternberg CN.Enzalutamide in metastatic prostate cancer before chemotherapy..N Engl J Med2014;371:424-33 PMCID:PMC4418931

[13] Smith MR,Chowdhury S,Hadaschik BA.Apalutamide treatment and metastasis-free survival in prostate cancer..N Engl J Med2018;378:1408-18

[14] Fizazi K,Tammela TL,Vjaters E.darolutamide in nonmetastatic, castration-resistant prostate cancer..N Engl J Med2019;380:1235-46

[15] Hussain M,Saad F,Shore N.Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer..N Engl J Med2018;378:2465-74

[16] Saraon P,Jarvi KA.Mechanisms of androgen-independent prostate cancer..EJIFCC2014;25:42-54 PMCID:PMC4975190

[17] Pisano C,Di Stefano RF,Scagliotti GV.The interplay between androgen receptor signalling and other molecular pathways in prostate cancer: new targets for treatment..Crit Rev Oncol Hemat.Forthcoming 2020;

[18] Davey RA.Androgen receptor structure, function and biology: from bench to bedside..Clin Biochem Rev2016;37:3-15 PMCID:PMC4810760

[19] Heemers HV.Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex..Endocr Rev2007;28:778-808

[20] Papakonstanti EA,Castanas E.A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors..Mol Endocrinol2003;17:870-81

[21] Lamont KR.Minireview: alternative activation pathways for the androgen receptor in prostate cancer..Mol Endocrinol2011;25:897-907 PMCID:PMC3100605

[22] Mostaghel EA,Montgomery B.Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit..Clin Cancer Res2014;20:791-8 PMCID:PMC3944407

[23] Mohler JL.Castration-recurrent prostate cancer is not androgen-independent..Adv Exp Med Biol2008;617:223-34

[24] Waltering KK,Visakorpi T.Androgen receptor (AR) aberrations in castration-resistant prostate cancer..Mol Cell Endocrinol2012;360:38-43

[25] Caffo O,Maines F,Spizzo G.Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide..Future Oncol2014;10:985-93

[26] Buttigliero C,Bertaglia V,Bironzo P.Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer..Cancer Treat Rev2015;41:884-92

[27] Al-Salama ZT.Apalutamide: a review in non-metastatic castration-resistant prostate cancer..Drugs2019;79:1591-8

[28] Chong JT,Liaw BC.Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date..Onco Targets Ther2018;11:2141-7 PMCID:PMC5905496

[29] Tucci M,Buttigliero C,Scagliotti GV.Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions..Onco Targets Ther2018;11:7353-68 PMCID:PMC6204864

[30] Edwards J,Grigor KM.Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer..Br J Cancer2003;89:552-6 PMCID:PMC2394367

[31] Crona DJ.Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance..Cancers (Basel)2017;9:67 PMCID:PMC5483886

[32] Taplin ME,Shuster TD,Spooner AE.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer..N Engl J Med1995;332:1393-8

[33] Dehm SM.Alternatively spliced androgen receptor variants..Endocr Relat Cancer2011;18:R183-96 PMCID:PMC3235645

[34] Antonarakis ES,Wang H,Nakazawa M.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer..N Engl J Med2014;371:1028-38 PMCID:PMC4201502

[35] Cai C.Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy..Endocr Relat Cancer2011;18:R175-82 PMCID:PMC3815562

[36] Mostaghel EA,Plymate SR,Balk S.Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants..Clin Cancer Res2011;17:5913-25 PMCID:PMC3184252

[37] Galletti G,Lam L.Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer..Cancer Treat Rev2017;57:16-27

[38] Puhr M,Eigentler A,Handle F.The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy..Clin Cancer Res2018;24:927-38

[39] Arora VK,Murali R,Wongvipat J.Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade..Cell2013;155:1309-22 PMCID:PMC3932525

[40] Yu Y,Xie N,Fazli L.Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control..J Clin Endocrinol Metab2013;98:2887-96 PMCID:PMC4078099

[41] Isikbay M,Kregel S,Cai Y.Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer..Horm Cancer2014;5:72-89 PMCID:PMC4440041

[42] Jayaram A,Mateo J,Kumar S.Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status..Ann Oncol2017;28:vii30

[43] Lamouille S,Derynck R.Molecular mechanisms of epithelial-mesenchymal transition..Nat Rev Mol Cell Biol2014;15:178-96 PMCID:PMC4240281

[44] Larue L.Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways..Oncogene2005;24:7443-54

[45] Montanari M,Cavaliere C,Malzone MG.Epithelial-mesenchymal transition in prostate cancer: an overview..Oncotarget2017;8:35376-89 PMCID:PMC5471062

[46] Shiota M,Takeuchi A,Kashiwagi E.Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer..Clin Cancer Res2014;20:951-61

[47] Baritaki S,Yeung K,Palladino M.Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction..Oncogene2009;28:3573-85

[48] Liu Q,Liu G,Do K.Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT..Cell Death Dis2017;8:e3007 PMCID:PMC5596596

[49] Mark M,Mey U,Rothermundt C.Impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-Pro): phase 2 pilot study..Clin Genitourin Cancer2019;17:e323-8

[50] Terry S.The many faces of neuroendocrine differentiation in prostate cancer progression..Front Oncol2014;4:60 PMCID:PMC3971158

[51] Aparicio AM,Corn PG,Araujo JC.Platinum-based chemotherapy for variant castrate-resistant prostate cancer..Clin Cancer Res2013;19:3621-30 PMCID:PMC3699964

[52] Wang HT,Li BG,Chang JW.Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis..J Clin Oncol2014;32:3383-90

[53] Beltran H,Mosquera JM,Puca L.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer..Nat Med2016;22:298-305 PMCID:PMC4777652

[54] Beltran H,Park K,Sboner A.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets..Cancer Discov2011;1:487-95 PMCID:PMC3290518

[55] Beltran H,Danila DC,Hoimes C.A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers..Clin Cancer Res2019;25:43-51 PMCID:PMC6320304

[56] Lin J,Sama AR,Kennedy B.A phase I/II study of the investigational drug Alisertib in combination with Abiraterone and Prednisone for patients with metastatic castration-resistant prostate cancer progressing on Abiraterone..Oncologist2016;21:1296-7e PMCID:PMC5189628

[57] Svensson C,Iglesias-Gato D,Pang ST.REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer..Nucleic Acids Res2014;42:999-1015 PMCID:PMC3902919

[58] Aparicio AM,Tapia EL,Chen HC.Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers..Clin Cancer Res2016;22:1520-30 PMCID:PMC4794379

[59] Tan HL,Rahimi HA,Gupta N.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma..Clin Cancer Res2014;20:890-903 PMCID:PMC3931005

[60] Sharma A,Ertel A,Clegg N.The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression..J Clin Invest2010;120:4478-92 PMCID:PMC2993601

[61] Ku SY,Wang Y,Seshadri M.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance..Science2017;355:78-83 PMCID:PMC5367887

[62] Carosella ED,LeMaoult J.A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G..Eur Urol2015;68:267-79

[63] Baumeister SH,Dranoff G.Coinhibitory pathways in immunotherapy for cancer..Annu Rev Immunol2016;34:539-73

[64] Schepisi G,Conteduca V,De Lisi D.Immunotherapy for prostate cancer: where we are headed..Int J Mol Sci2017;18:2627 PMCID:PMC5751230

[65] Taylor BS,Hieronymus H,Xiao Y.Integrative genomic profiling of human prostate cancer..Cancer Cell2010;18:11-22 PMCID:PMC3198787

[66] Bishop JL,Angeles A,Azad AA.PD-L1 is highly expressed in Enzalutamide resistant prostate cancer..Oncotarget2015;6:234-42 PMCID:PMC4381591

[67] Hansen A,Ott PA,Lopez J.Pembrolizumab for patients with advanced prostate adenocarcinoma: preliminary results from the KEYNOTE-028 study..Ann Oncol2016;27:243-65

[68] De Bono JS,Ojamaa K,Drake CG.KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)..J Clin Oncol2018;36:5007

[69] Graff JN,Drake CG,Redmond WL.Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer..Oncotarget2016;7:52810-7 PMCID:PMC5288150

[70] Drake CG,Fizazi K,van den Eertwegh AJM.Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC)..J Clin Oncol2014;32:2

[71] Brahmer JR,Wollner I,Picus J.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates..J Clin Oncol2010;28:3167-75 PMCID:PMC4834717

[72] Topalian SL,Brahmer JR,Smith DC.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer..N Engl J Med2012;366:2443-54 PMCID:PMC3544539

[73] Kim JW,Massard C,Harshman LC.A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)..J Clin Oncol2018;36:187

[74] Small EJ,Higano CS,Nemunaitis JJ.Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer..J Clin Oncol2006;24:3089-94

[75] Shiota M,Takeuchi A,Cordonnier T.Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer..Oncotarget2015;6:9086-98 PMCID:PMC4496204

[76] Gao S,Gerrin S,Sharma A.ErbB2 signaling increases androgen receptor expression in Abiraterone-resistant prostate cancer..Clin Cancer Res2016;22:3672-82 PMCID:PMC4947432

[77] Taylor BS,Hieronymus H,Xiao Y.Integrative genomic profiling of human prostate cancer..Cancer Cell2010;18:11-22 PMCID:PMC3198787

[78] Robinson D,Wu YM,Lonigro RJ.Integrative clinical genomics of advanced prostate cancer..Cell2015;161:1215-28 PMCID:PMC4484602

[79] Carver BS,Wongvipat J,Chen Y.Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer..Cancer Cell2011;19:575-86 PMCID:PMC3142785

[80] Thomas C,Crafter C,Beraldi E.Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo..Mol Cancer Ther2013;12:2342-55

[81] Kolinsky MP,Bianchini D,Mehra N.A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer..Ann Oncol2020;31:619-25 PMCID:PMC7217345

[82] He C,Dong L,Hu Q.Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells..Prostate2017;77:1187-98 PMCID:PMC5527967

[83] Graham L,Torres A,Chen Y.A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer..Invest New Drugs2018;36:458-67 PMCID:PMC6050986

[84] Sweeney C,Babu S,Mehlhaff BA.Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone..J Clin Oncol2019;37:5009

[85] Wei XX,Kim W,Lin AM.A phase i study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer..Oncologist2017;22:e503-43 PMCID:PMC5423513

[86] de Bono JS,Rodrigues DN,Bracarda S.Randomized phase II study evaluating Akt blockade with Ipatasertib, in combination with Abiraterone, in patients with metastatic prostate cancer with and without PTEN loss..Clin Cancer Res2019;25:928-36

[87] Farrow JM,Evans CP.Autophagy as a modulator and target in prostate cancer..Nat Rev Urol2014;11:508-16 PMCID:PMC4415606

[88] Fulda S.Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy..Oncogene2015;34:5105-13

[89] Bennett HL,Fleming JT,O’Prey J.Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?.BJU Int2013;111:672-82

[90] Nguyen HG,Kung HJ,Tilki D.Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model..Oncogene2014;33:4521-30 PMCID:PMC4155805

[91] Matsumoto H,Shiota M,Beraldi E.Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability..Cancer Res2013;73:5206-17

[92] Asangani IA,Wang X,Cieslik M.Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer..Nature2014;510:278-82 PMCID:PMC4075966

[93] Asangani IA,Dommeti VL,Apel IJ.BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer..Mol Cancer Res2016;14:324-31 PMCID:PMC4834259

[94] Miyata Y,Mitsunari K,Ohba K.Met in urological cancers..Cancers (Basel)2014;6:2387-403 PMCID:PMC4276973

[95] Verras M,Xue H,Wang Y.The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression..Cancer Res2007;67:967-75

[96] Sweeney C,Harshman LC,Choueiri TK.Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): an investigator-sponsored study..J Clin Oncol2014;32:5027

[97] Smith M,Sternberg C,Oudard S.Phase III study of Cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1..J Clin Oncol2016;34:3005-13

[98] Nadiminty N,Liu C,Lou W.NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants..Mol Cancer Ther2013;12:1629-37 PMCID:PMC3941973

[99] Mateo J,Sandhu S,Mossop H.DNA-repair defects and olaparib in metastatic prostate cancer..N Engl J Med2015;373:1697-708 PMCID:PMC5228595

[100] Goodwin JF,Dean JL,de Leeuw R.A hormone-DNA repair circuit governs the response to genotoxic insult..Cancer Discov2013;3:1254-71 PMCID:PMC3823813

[101] Tarish FL,Tanoglidi A,Letocha H.Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair..Sci Transl Med2015;7:312re11

[102] Asim M,Zecchini HI,Gelali E.Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer..Nat Commun2017;8:374 PMCID:PMC5575038

[103] Li L,Yang G,Park S.Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer..Sci Signal2017;10:eaam7479 PMCID:PMC5855082

[104] Clarke N,Alekseev B,Jones R.Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial..Lancet Oncol2018;19:975-86